Revance Therapeutics to Present in the 27th Annual

NEWARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ: RVNC ), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the Company plans to participate in the 27 ^th Annual Piper Jaffray Healthcare Conference in New York, NY.

Revance management is scheduled for a fireside chat on Tuesday, December 1, 2015 at 3:00pm ET. Interested parties can access the live audio webcast at http://investors.revance.com/index.cfm . An archived audio replay will be available on the website for 30 days.

About Revance Therapeutics, Inc. Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com .

" Revance Therapeutics," TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Investors: Revance Therapeutics Jeanie Herbert (714) 325-3584 Westwicke Partners Leigh Salvo (415) 513-1281 Trade Media: Nadine Tosk (847) 920-9858